File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3390/cells9112448
- Scopus: eid_2-s2.0-85096081261
- PMID: 33182616
- WOS: WOS:000592847800001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Early Treatment of Interleukin-33 can Attenuate Lupus Development in Young NZB/W F1 Mice
Title | Early Treatment of Interleukin-33 can Attenuate Lupus Development in Young NZB/W F1 Mice |
---|---|
Authors | |
Keywords | Interleukin-33 cytokine systemic lupus erythematosus regulatory B cells autoimmune diseases |
Issue Date | 2020 |
Publisher | MDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cells |
Citation | Cells, 2020, v. 9 n. 11, p. article no. 2448 How to Cite? |
Abstract | Interleukin-33 (IL-33), a member of the IL-1 cytokine family, has been recently associated with the development of autoimmune diseases, including systemic lupus erythematosus (SLE). IL-33 is an alarmin and a pleiotropic cytokine that affects various types of immune cells via binding to its receptor, ST2. In this study, we determine the impact of intraperitoneal IL-33 treatments in young lupus, NZB/W F1 mice. Mice were treated from the age of 6 to 11 weeks. We then assessed the proteinuria level, renal damage, survival rate, and anti-dsDNA antibodies. The induction of regulatory B (Breg) cells, changes in the level of autoantibodies, and gene expression were also examined. In comparison to the control group, young NZB/W F1 mice administered with IL-33 had a better survival rate as well as reduced proteinuria level and lupus nephritis. IL-33 treatments significantly increased the level of IgM anti-dsDNA antibodies, IL-10 expressing Breg cells, and alternatively-induced M2 macrophage gene signatures. These results imply that IL-33 exhibits a regulatory role during lupus onset via the expansion of protective IgM anti-dsDNA as well as regulatory cells such as Breg cells and M2 macrophages. |
Persistent Identifier | http://hdl.handle.net/10722/306510 |
ISSN | 2023 Impact Factor: 5.1 2023 SCImago Journal Rankings: 1.547 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | JAYA, FNM | - |
dc.contributor.author | LIU, Z | - |
dc.contributor.author | Chan, GCF | - |
dc.date.accessioned | 2021-10-22T07:35:38Z | - |
dc.date.available | 2021-10-22T07:35:38Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Cells, 2020, v. 9 n. 11, p. article no. 2448 | - |
dc.identifier.issn | 2073-4409 | - |
dc.identifier.uri | http://hdl.handle.net/10722/306510 | - |
dc.description.abstract | Interleukin-33 (IL-33), a member of the IL-1 cytokine family, has been recently associated with the development of autoimmune diseases, including systemic lupus erythematosus (SLE). IL-33 is an alarmin and a pleiotropic cytokine that affects various types of immune cells via binding to its receptor, ST2. In this study, we determine the impact of intraperitoneal IL-33 treatments in young lupus, NZB/W F1 mice. Mice were treated from the age of 6 to 11 weeks. We then assessed the proteinuria level, renal damage, survival rate, and anti-dsDNA antibodies. The induction of regulatory B (Breg) cells, changes in the level of autoantibodies, and gene expression were also examined. In comparison to the control group, young NZB/W F1 mice administered with IL-33 had a better survival rate as well as reduced proteinuria level and lupus nephritis. IL-33 treatments significantly increased the level of IgM anti-dsDNA antibodies, IL-10 expressing Breg cells, and alternatively-induced M2 macrophage gene signatures. These results imply that IL-33 exhibits a regulatory role during lupus onset via the expansion of protective IgM anti-dsDNA as well as regulatory cells such as Breg cells and M2 macrophages. | - |
dc.language | eng | - |
dc.publisher | MDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cells | - |
dc.relation.ispartof | Cells | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Interleukin-33 | - |
dc.subject | cytokine | - |
dc.subject | systemic lupus erythematosus | - |
dc.subject | regulatory B cells | - |
dc.subject | autoimmune diseases | - |
dc.title | Early Treatment of Interleukin-33 can Attenuate Lupus Development in Young NZB/W F1 Mice | - |
dc.type | Article | - |
dc.identifier.email | Chan, GCF: gcfchan@hku.hk | - |
dc.identifier.authority | Chan, GCF=rp00431 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3390/cells9112448 | - |
dc.identifier.pmid | 33182616 | - |
dc.identifier.pmcid | PMC7696801 | - |
dc.identifier.scopus | eid_2-s2.0-85096081261 | - |
dc.identifier.hkuros | 328486 | - |
dc.identifier.volume | 9 | - |
dc.identifier.issue | 11 | - |
dc.identifier.spage | article no. 2448 | - |
dc.identifier.epage | article no. 2448 | - |
dc.identifier.isi | WOS:000592847800001 | - |
dc.publisher.place | Switzerland | - |